Onco Actu du 29 octobre 2015

	2.11 Etiologie - Alimentation
Meat as a Cause of Cancer [NY Times] The latest cancer report from the World Health Organization provides persuasive evidence that eating meat can cause cancer, but the risk is very small for most people.
	3.1 Tabac
E-Cigarettes Appeal to Smokers Who Are Trying to Quit, Study Says [Wall Street Journal] U.S. study supports claims by advocates of the battery-powered devices.
	4.9 Dép., diag. & prono. - Sein
This may explain why more deaths aren't prevented by breast cancer screening [LA Times] If we keep expecting breast cancer to behave like prostate cancer, the result may be “screening programs that are not helpful,” they wrote. Even worse, it could lead to “administration of treatment that is either not needed or not effective.”
Mammograms not catching worst cancers before they spread -US study [The Guardian] Dr Barnett Kramer, a screening expert at the National Cancer Institute, said the report in NEJM showed the limitations of mammography.
	5.10 Traitements - Essais
Landmark clinical trial shows gene-targeted drug can treat prostate cancer [The Institute of Cancer Research] The trial is a milestone in cancer treatment as the first to show the benefits of ‘precision medicine’ in prostate cancer – with treatment matched to the particular genetic characteristics of a man’s tumour.
Men with advanced prostate cancer could benefit from ‘targeted’ drug [Cancer Research UK] “The next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them."
'Milestone' prostate cancer drug [BBC News] The drug, olaparib, had low overall success, but slowed tumour growth in 88% of patients with specific DNA mutations.
	5.12 Immunothérapies
Amgen's Imlygic May Not Boost Earnings But It Will Change Cancer Care [Forbes] But what’s most important about Imlygic and all the other oncolytic viruses in development is probably not their potential as standalone therapies. Virtually everyone working in the field agrees that the biggest potential for these engineered bugs will be in combination treatments, particularly with other types of immune-boosting treatments.
FDA Approves First in a New Class of Immunotherapies [CRI] Watch an animated video below that explains how oncolytic virus therapy works.
	5.2 Pharma
Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product [BMS] Bristol-Myers Squibb was recognized for its innovative discovery and development of Opdivo in approved indications for previously treated metastatic squamous non-small cell lung cancer (NSCLC), and in unresectable or metastatic melanoma and disease progression following Yervoy (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor, for which it received accelerated approval based on tumor response rate and durability of response.
IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent [AbbVie] Considered to be the biomedical industry's highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies.
	5.2.1 Pharma - Partenariats
Servier severs a $450M oncology deal with MacroGenics [FierceBiotech] Per the agreement, Servier had the option to opt in or out on enoblituzumab's future after Phase I. MacroGenics presented its partner with the data in July, and Servier had 90 days to make up its mind.
	5.3 Traitements - FDA, EMA,...
EMA launches scheme to prioritise medicines access for patients [Pharmafile] The PRIME scheme aims to strengthen the support it offers pharma companies for medicines that have the potential to benefit patients who presently have no treatment options, or that may offer a major therapeutic advantage over existing treatments.
FDA Seeks Info on New Tech Helping Conduct Clinical Research [RAPS] More specifically, the agency said it's "aware of several groups conducting and interested in conducting clinical investigations using mobile technology and remote methods for data collection."
	5.3.4 Traitements - AMM (FDA, EMA)
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma [BMS] First company to demonstrate the potential of an immune checkpoint inhibitor in the adjuvant treatment for these patients.
FDA approves Yervoy to reduce the risk of melanoma returning after surgery [FDA] “This new use of the drug in earlier stages of the disease builds on our understanding of the immune system’s interaction with cancer.”
FDA expands use of Bristol Myers' cancer drug Yervoy [Reuters] The drug, known chemically as ipilimumab, raked in global sales of $240 million in the quarter ended Sept. 30, 2015.
	6.1 Observation
Where cancer patients live could influence late diagnosis [Cancer Research UK] Almost half the cancer patients in Merseyside (49 per cent) are diagnosed late compared to 40 per cent of patients in the South West, according to a Cancer Research UK analysis of data that recorded the stage of diagnosis in around two-thirds of all cancer cases in England.
	6.11 Patients
How cancer treatments can affect your sex life [The Globe and Mail] Unfortunately, many doctors do not adequately discuss before treatment the sexual changes that are likely to occur, nor do they introduce alternative ways of experiencing and taking pleasure in sex.
	6.4 Médico-éco
$20 million Commonwealth Foundation for Cancer Research gift to expand collaborative cancer research [MIT News] Gift will augment the Bridge Project, a collaborative project between the Dana-Farber/Harvard Cancer Center and MIT's Koch Institute.